I've done a few; I consider them special situations, but you might just call them non-core holdings.
In November 2009, Cedar Fair plummeted as it suspended its distribution due to a debt covenant. The problem was that it is a public partnership, so investors pay their share of the company's income tax directly and that distribution, in part, covered those payments. Most investors were in it for the 7% dividend, not to pay money, so they left in droves. My calculus at the time was that if 2010 was worse than 2009, the company could technically go bankrupt (violating further covenants, but still profitable). But if 2010 reverted to the mean, the distribution would be 25% on the Nov 2009 price, in addition to the price appreciation. Not only did the latter happen, but an activist investor became involved when the management tried to take the company private at $15. The price multiplied by several times over the next few years. Note that I wouldn't do this now; the price never matched 2009, even at the March lows. And the risk is much higher with a blown summer season and uncertainty about next year.
I sweated through that one at every step, but it was a lot of fun. I earned a lot, and learned a lot.
This time around, I am finding a lot of success with small biotech firms who have FDA-approved drugs, but whose introduction of those has been impacted or interrupted outright due to Covid. I have had two buyouts this year--AIMT and BSTC. The only sad part about those is that it's short term gains. I am currently looking at ARDX, which while not yet approved has an NDA submitted with good data, and looks to launch in April.